178 related articles for article (PubMed ID: 23955683)
41. Reduced annexin II protein expression in high-grade prostatic intraepithelial neoplasia and prostate cancer.
Yee DS; Narula N; Ramzy I; Boker J; Ahlering TE; Skarecky DW; Ornstein DK
Arch Pathol Lab Med; 2007 Jun; 131(6):902-8. PubMed ID: 17550317
[TBL] [Abstract][Full Text] [Related]
42. A molecular correlate to the Gleason grading system for prostate adenocarcinoma.
True L; Coleman I; Hawley S; Huang CY; Gifford D; Coleman R; Beer TM; Gelmann E; Datta M; Mostaghel E; Knudsen B; Lange P; Vessella R; Lin D; Hood L; Nelson PS
Proc Natl Acad Sci U S A; 2006 Jul; 103(29):10991-6. PubMed ID: 16829574
[TBL] [Abstract][Full Text] [Related]
43. Expression of p14ARF, p15INK4b, p16INK4a, and DCR2 increases during prostate cancer progression.
Zhang Z; Rosen DG; Yao JL; Huang J; Liu J
Mod Pathol; 2006 Oct; 19(10):1339-43. PubMed ID: 16799475
[TBL] [Abstract][Full Text] [Related]
44. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
Cornford PA; Dodson AR; Parsons KF; Desmond AD; Woolfenden A; Fordham M; Neoptolemos JP; Ke Y; Foster CS
Cancer Res; 2000 Dec; 60(24):7099-105. PubMed ID: 11156417
[TBL] [Abstract][Full Text] [Related]
45. Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence.
Velasco A; Hewitt SM; Albert PS; Hossein M; Rosenberg H; Martinez C; Sagalowsky AI; McConnell JD; Marston W; Leach FS
Cancer; 2002 Feb; 94(3):690-9. PubMed ID: 11857301
[TBL] [Abstract][Full Text] [Related]
46. Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia.
Marchal C; Redondo M; Padilla M; Caballero J; Rodrigo I; García J; Quian J; Boswick DG
Histol Histopathol; 2004 Jul; 19(3):715-8. PubMed ID: 15168332
[TBL] [Abstract][Full Text] [Related]
47. ETS2 is a prostate basal cell marker and is highly expressed in prostate cancers aberrantly expressing p63.
Torres A; Alshalalfa M; Davicioni E; Gupta A; Yegnasubramanian S; Wheelan SJ; Epstein JI; De Marzo AM; Lotan TL
Prostate; 2018 Sep; 78(12):896-904. PubMed ID: 29761525
[TBL] [Abstract][Full Text] [Related]
48. Association of microRNA-21 expression with clinicopathological characteristics and the risk of progression in advanced prostate cancer patients receiving androgen deprivation therapy.
Guan Y; Wu Y; Liu Y; Ni J; Nong S
Prostate; 2016 Aug; 76(11):986-93. PubMed ID: 27040772
[TBL] [Abstract][Full Text] [Related]
49. Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate Cancers.
Burdelski C; Fitzner M; Hube-Magg C; Kluth M; Heumann A; Simon R; Krech T; Clauditz T; Büscheck F; Steurer S; Wittmer C; Hinsch A; Luebke AM; Jacobsen F; Minner S; Tsourlakis MC; Beyer B; Steuber T; Thederan I; Sauter G; Izbicki J; Schlomm T; Wilczak W
Neoplasia; 2017 Apr; 19(4):279-287. PubMed ID: 28282546
[TBL] [Abstract][Full Text] [Related]
50. Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies.
Tomlins SA; Palanisamy N; Siddiqui J; Chinnaiyan AM; Kunju LP
Arch Pathol Lab Med; 2012 Aug; 136(8):935-46. PubMed ID: 22849743
[TBL] [Abstract][Full Text] [Related]
51. The distribution of PAX-2 immunoreactivity in the prostate gland, seminal vesicle, and ejaculatory duct: comparison with prostatic adenocarcinoma and discussion of prostatic zonal embryogenesis.
Quick CM; Gokden N; Sangoi AR; Brooks JD; McKenney JK
Hum Pathol; 2010 Aug; 41(8):1145-9. PubMed ID: 20413145
[TBL] [Abstract][Full Text] [Related]
52. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker.
Darson MF; Pacelli A; Roche P; Rittenhouse HG; Wolfert RL; Young CY; Klee GG; Tindall DJ; Bostwick DG
Urology; 1997 Jun; 49(6):857-62. PubMed ID: 9187691
[TBL] [Abstract][Full Text] [Related]
53. DOC-2/DAB2 interacting protein status in high-risk prostate cancer correlates with outcome for patients treated with radiation therapy.
Jacobs C; Tumati V; Kapur P; Yan J; Hong D; Bhuiyan M; Xie XJ; Pistenmaa D; Yu L; Hsieh JT; Saha D; Kim DW
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):729-35. PubMed ID: 24867541
[TBL] [Abstract][Full Text] [Related]
54. Immunohistochemical expression of Ets-related gene-transcriptional factor in adenocarcinoma prostate and its correlation with Gleason score.
Mannan R; Bhasin TS; Manjari M; Singh G; Bhatia PK; Sharma S
Indian J Pathol Microbiol; 2016; 59(4):489-495. PubMed ID: 27721279
[TBL] [Abstract][Full Text] [Related]
55. CXXC5 expression in prostate cancer: implications for cancer progression.
Benedetti I; De Marzo AM; Geliebter J; Reyes N
Int J Exp Pathol; 2017 Aug; 98(4):234-243. PubMed ID: 29027288
[TBL] [Abstract][Full Text] [Related]
56. High NRBP1 expression in prostate cancer is linked with poor clinical outcomes and increased cancer cell growth.
Ruiz C; Oeggerli M; Germann M; Gluderer S; Stocker H; Andreozzi M; Thalmann GN; Cecchini MG; Zellweger T; Stürm S; Koivisto PA; Helin HJ; Gelmann EP; Glass AG; Gasser TC; Terracciano LM; Bachmann A; Wyler S; Bubendorf L; Rentsch CA
Prostate; 2012 Nov; 72(15):1678-87. PubMed ID: 22473923
[TBL] [Abstract][Full Text] [Related]
57. Loss of YAP protein in prostate cancer is associated with Gleason score increase.
Hu X; Jia Y; Yu J; Chen J; Fu Q
Tumori; 2015; 101(2):189-93. PubMed ID: 25908048
[TBL] [Abstract][Full Text] [Related]
58. PBOV1 as a potential biomarker for more advanced prostate cancer based on protein and digital histomorphometric analysis.
Carleton NM; Zhu G; Gorbounov M; Miller MC; Pienta KJ; Resar LMS; Veltri RW
Prostate; 2018 May; 78(7):547-559. PubMed ID: 29520928
[TBL] [Abstract][Full Text] [Related]
59. Immunohistochemical evaluation of ERG expression in various benign and malignant tissues.
Liu H; Shi J; Wilkerson M; Yang XJ; Lin F
Ann Clin Lab Sci; 2013; 43(1):3-9. PubMed ID: 23462600
[TBL] [Abstract][Full Text] [Related]
60. Autophagy proteins in prostate cancer: relation with anaerobic metabolism and Gleason score.
Giatromanolaki A; Sivridis E; Mendrinos S; Koutsopoulos AV; Koukourakis MI
Urol Oncol; 2014 Jan; 32(1):39.e11-8. PubMed ID: 23787295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
